Chandra Bhagat Pharma (BSE: CBPL) had a P/E of 13.7× on 6 Nov 2026, below the industry P/E of 36.7×. Sales fell 2.1% a year over 3 years while net profit grew 50%, with ROCE of 17% and ROE of 9.7%. Debt is 0.50× equity. It is listed on an SME platform with a market cap of ₹42 Cr, ranked 7th of 11 Medical Distribution companies by market cap; the shares rose 45% over the past year.
- ₹56.00
- ₹56.00
- ₹55.50
- ₹58.00
- 2K
Health check
- ReturnsIn line
+45.0% over a year, better than 4 of 7 peers.
- Price tagCheaper
P/E 13.7 vs industry 36.7.
- GrowthSlow
Sales −2.1%, profit +49.8% a year over 3 years.
- ProfitabilityAverage
ROCE 16.7% vs peer median 7.4%.
- Balance sheetFair
Debt 0.50× equity, interest covered 3.0×.
- Red flagsNone found
No warning signs in the headline numbers.
Small cap
Defensive
Key metrics
- Market cap
- ₹42 Cr
- Small cap
- P/E
- 13.7
- Industry 36.7
- Price to book
- 1.26
- Peers 1.99
- Dividend yield
- 0.00%
- ROE
- 9.7%
- Peers 6.7%
- ROCE
- 16.7%
- Peers 7.4%
- Debt to equity
- 0.50
- Debt ₹17 Cr
- EPS (TTM)
- ₹4.04
- OPM (TTM)
- 2.5%
- Net margin 2.6%
- Sales growth
- +251.7%
- Latest quarter vs a year ago
- Profit growth
- +1393.9%
- Latest quarter vs a year ago
- Price to sales
- 0.36
- EV/EBITDA 11.3
Strengths and risks
Strengths
- Quarterly profit up 1393.9% on a year ago.
- Quarterly sales up 251.7% on a year ago.
- P/E of 13.7 against an industry P/E of 36.7.
About Chandra Bhagat Pharma
Chandra Bhagat Pharma Limited, a pharmaceutical company, markets pharmaceutical critical care and health care products in India and internationally. The company offers pharmaceutical formulations, including intravenous and intramuscular injections, oral solids, tablets, capsules, liquid orals, syrup suspensions, injectable liquids, powders, lyophilized ampoules, vials, prefilled syringes, and small and large volume parenteral for various therapeutic…
- Headquarters
- Mumbai
- Employees
- 45
- Sector
- Healthcare
- ISIN
- INE07QQ01016
- Website
- cbcpharma.com
Price range
- Avg volume (3M)
- 3K
- 1-year return
- plus 45.0%
- From 52-week high
- minus 7.6%
Peers · Medical Distribution
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTEROEntero Healthcare Solutions | 1,900.40 | plus 8.34% | 8,279 | 66.0 | 4.90 | 11.3% | 6.7% | 4.4% | 25.7% | – | 0.00% | plus 62.4% |
| APPLAptus Pharma | 465.00 | plus 0.92% | 797 | 100.2 | 28.06 | 29.3% | 31.7% | 15.4% | 49.6% | 187.5% | 0.00% | plus 772.6% |
| ARVAYAArvaya Healthcare | 111.00 | minus 4.31% | 576 | – | – | 1.4% | 2.2% | 0.0% | 193.6% | – | 0.00% | plus 143.1% |
| EVEXIAEvexia Lifecare | 1.46 | minus 3.31% | 274 | 146.0 | 0.67 | 0.3% | 0.3% | 1.6% | 16.6% | 34.5% | 0.00% | minus 15.2% |
| NOVELIXNovelix Pharmaceuticals | 64.66 | minus 4.91% | 184 | 36.7 | 2.93 | 7.4% | 8.0% | 3.1% | 354.8% | – | 0.00% | plus 29.5% |
| AMWILLAmwill Health Care | 44.00 | plus 5.67% | 88 | 7.8 | 1.06 | 15.5% | 14.4% | 14.1% | 14.7% | 54.2% | 2.27% | minus 25.4% |
| CBPLChandra Bhagat Pharma | 55.50 | minus 4.31% | 42 | 13.7 | 1.26 | – | 9.7% | 2.5% | – | – | 0.00% | plus 45.0% |
| WELCUREWelcure Drugs and Pharmaceuticals | 0.18 | minus 5.26% | 22 | – | 0.23 | −5.7% | −5.5% | −1.5% | – | – | 0.00% | minus 62.7% |
| Median of 7 peers | – | −3.31% | 274 | 66.0 | 1.99 | 7.4% | 6.7% | 3.1% | 37.7% | 54.2% | 0.00% | 29.5% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- −2.1%
- Profit CAGR 3Y
- +49.8%
- ROE
- 9.7%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 120 | 221 | 86.7 | 112 | |
| – | +85.0% | minus 60.8% | +29.3% | |
| 116 | 227 | 85.7 | 106 | |
| 4.1 | −6 | 1 | 5.7 | |
| 3.4% | −2.7% | 1.2% | 5.1% | |
| 0.1 | 9.4 | 2.6 | 2.7 | |
| 2.2 | 1.3 | 1.8 | 1.9 | |
| 0.1 | 0.5 | 0.9 | 1 | |
| −0.7 | 0.6 | 0.3 | −1.4 | |
| 1.2 | 2.3 | 1.2 | 4.1 | |
| 22.1% | 32.3% | 26.4% | 25.8% | |
| 0.9 | 1.5 | 0.9 | 3 | |
| – | +69.0% | minus 43.9% | +255.1% | |
| 1.20 | 2.03 | 1.14 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 7.5 | 7.5 | 7.5 | 7.5 | |
| 19.9 | 21.5 | 22.4 | 25.6 | |
| 18.9 | 16.4 | 20.9 | 16.5 | |
| 14.2 | 56.4 | 50.7 | 44.6 | |
| 60.6 | 102 | 102 | 94.2 | |
| 0.7 | 2.5 | 2.6 | 2.6 | |
| 6.5 | 5.1 | 0.8 | 4.8 | |
| 53.3 | 94.2 | 98.1 | 86.8 | |
| 60.6 | 102 | 102 | 94.2 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 5.3 | 6.2 | −5.7 | 9.2 | |
| −0.1 | −1.9 | −0.8 | −0.4 | |
| −4.4 | −5.8 | 2.2 | −6.4 | |
| 0.8 | −1.5 | −4.3 | 2.4 | |
| −0.4 | −2.3 | −1.2 | −0.9 | |
| 4.9 | 3.9 | −6.9 | 8.3 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.